sinusitis News
-
Article in Journal of Magnetism and Magnetic Materials
October 10, 2016: Publication accepted by the Journal of Magnetism and Magnetic Materials on biofilm disruption with rotating micro-rods, in order to enhance efficacy of antibiotics (under image-guidance of WMP-designed systems). Biofilms have been implicated in many difficult-to-treat diseases, including chronic sinusitis and pressure ...
-
Sinusleeve™ Balloon Device Completes FDA Listing, Dalent Medical Begins Sales in South Florida
Dalent Medical, a Miami-based company developing innovative devices for Ear, Nose & Throat Doctors is pleased to announce that the Sinusleeve™ Balloon Sinus Dilation Sleeve has completed the United States Food and Drug Administration’s listing process. The company will begin selling the Sinusleeve™ balloon device in their home state of Florida to Otolaryngologists ...
-
Intersect ENT Receives CE Mark Approval for PROPEL Contour for Patients with Chronic Rhinosinusitis Following Frontal Sinus Surgery
Intersect ENT, Inc. (Nasdaq: XENT), a global ear, nose and throat (“ENT”) medical technology leader dedicated to transforming patient care, today announced it has received CE Mark approval for the company’s PROPEL Contour (mometasone furoate) sinus implant enabling sales and distribution in the European Union. The Contour CE approval expands the portfolio of PROPEL products ...
-
Dalent Medical Secures $1.5 Million Round, Granted Patent Protecting New Medical Device for ENT Physicians
Dalent Medical, a Miami-based company developing innovative devices for Ear, Nose & Throat doctors is pleased to announce the closing of a $1.5 million funding round. The company has raised over $2 million from private investors since 2018. The additional funds will be used to produce inventory and ramp up sales & marketing to support the rollout of the company’s first patented ...
-
Intersect ENT Announces Launch of the New Straight Delivery System Packaged with the PROPEL Mini Sinus Implant
Intersect ENT®, Inc. (Nasdaq: XENT), a global ear, nose and throat (“ENT”) medical technology leader dedicated to transforming patient care, today announced the U.S. availability of the new Straight Delivery System (“SDS”) packaged with the company’s PROPEL® Mini (mometasone furoate) Sinus Implant. The combined packaging of the SDS with PROPEL Mini received ...
-
Real-World Evidence Study Demonstrates Intersect ENT’s PROPEL Sinus Implant Reduces Healthcare Resource Utilization
Real-World Evidence Study Demonstrates Intersect ENT’s PROPEL® Sinus Implant Reduces Healthcare Resource Utilization Data from first-of-its-kind study published in Current Medical Research and Opinion Patients receiving PROPEL® following endoscopic sinus surgery had statistically significant lower healthcare resource utilization over a postoperative period of 18 months, ...
-
Miamitech Startup Spotlight: Dalent Aims to Improve Sinus Surgery Experience, Outcome and Cost
If you’ve ever had an awful sinus infection, you know how painful, and quite frankly, how much of a drag it is. But most of us don’t have Chronic Sinusitis, which consists of a sinus infection lasting longer than 3 months (despite treatment), according to the Mayo Clinic. That being said, 11.6% of the American population does, says the CDC. For years, if doctors couldn’t bring ...
-
Creative Enzymes Introduces Chitinases for Research and Industrial Production
Creative Enzymes, a professional enzyme provider located in New York, USA, is always hammering away at research and trials in order to provide customers with as many enzyme services and products as possible. Creative Enzymes recently announced Chitinases for research and industrial production. Chitin widely exists in the shells of crustaceans, the carapaces of insects and the cell walls of ...
-
Preventing Outbreaks of Streptococcus pneumoniae Infections
Until 2000, Streptococcus pneumoniae infections caused 100,000-135,000 hospitalizations for pneumonia, 6 million cases of ear infections, and 60,000 cases of invasive disease, including 3300 cases of meningitis. Disease figures have improved since a pneumococcal conjugate vaccine was introduced in 2001. Streptococcus pneumoniae, or pneumococcus, is a type of Gram-positive bacteria. It can ...
-
Streptococcus pneumoniae Exposed in New Online Video
Today, the IAQ Video Network and Cochrane & Associates announced the release of another online video to help educate the public about issues that may impact their health. The latest educational video discusses Streptococcus pneumoniae infections and how they may impact human health. Streptococcus pneumoniae, or pneumococcus, is a type of Gram-positive bacteria. It can often be found in ...
-
U.S. Nationwide Commercial Availability of the VenSure Balloon Sinus Dilation System and Cube Navigation System Highlight Intersect ENT’s Continued Commitment to Providing Innovative, Solutions for Patients with Chronic Rhinosinusitis
Intersect ENT®, Inc. (Nasdaq: XENT), a global ear, nose and throat (“ENT”) medical technology leader dedicated to transforming patient care, today announced the U.S. nationwide commercial availability of the VenSure™ Balloon Sinus Dilation System and Cube™4D Navigation System with VirtuEye™ photo registration. The VenSure Balloon and Cube 4D Navigation Systems ...
-
Successful SARS-CoV-2 trial with Ondine’s nasal photodisinfection
Clínica Universidad de Navarra has completed a randomised controlled study of Ondine Biomedical’s nasal photodisinfection technology in fully vaccinated COVID-19 patients with early symptoms of COVID-19. “Top-line results from this clinical trial suggest that nasal photodisinfection treatment rapidly and substantially suppresses SARS-CoV-2 viral replication and infectivity in ...
-
Infrared Coagulation of The Inferior Turbinate: A new treatment for refractory chronic rhinitis
Nasal obstruction remains a challenge to the modem day rhinologist. In the evolving climate of "cost containment" and "risk-outcome analyses", office-based inferior turbinate reduction has regained popularity. This article describes a new method to reduce nasal obstruction in patients with chronic rhinitis when conventional medical therapy has failed. Rhinitis is chronic (CR) when symptoms of ...
-
WHO calls for new innovations to tackle antimicrobial resistance crisis
Antimicrobial resistance (AMR) threatens the effective prevention and treatment of an ever-increasing range of infections caused by bacteria, parasites, viruses and fungi Ondine’s nonantibiotic photodisinfection technology has been proven in Canadian hospitals to kill pathogens helping to generate 84% reduction of postoperative infection rates and significant cost savings. The World ...
-
Lyra Therapeutics Announces Publication of Preclinical Pharmacokinetics and Drug Release characterization for XTreo™ Technology Platform in the American Journal of Rhinology & Allergy
Outcomes supported advancing into clinical development for LYRA’s first indication, Chronic Rhinosinusitis, with lead product candidate, LYR-210, currently poised to enter Phase 3 studies Lyra Therapeutics, Inc. (Nasdaq: LYRA), a clinical-stage therapeutics company leveraging its proprietary XTreo™ platform to enable precise, sustained, and local delivery of medications to the ear, ...
-
Expand Post-Market Study Evaluating Longer-Term Outcomes of PROPEL Contour Sinus Implant in the Frontal Sinus Ostia Following In-Office Balloon Sinus Dilation
Intersect ENT®, Inc. (Nasdaq: XENT), a global ear, nose and throat (“ENT”) medical technology leader dedicated to transforming patient care, today announced that it began the process of initiating the Company’s EXPAND Clinical Study by successfully registering on ClinicalTrials.gov (NCT04858802). EXPAND is a prospective, randomized, single-blind, intra-patient controlled, ...
-
Vaxcyte Announces FDA Clearance of Investigational New Drug Application for VAX-24 for the Prevention of Invasive Pneumococcal Disease
Company Expects to Deliver Topline Immunogenicity Results from the Phase 1/2 Clinical Study by End of 2022 VAX-24 is a 24-Valent Pneumococcal Conjugate Vaccine Candidate Designed to Provide Broad-Spectrum Protection Vaxcyte, Inc. (Nasdaq: PCVX), a vaccine innovation company engineering high-fidelity vaccines to protect humankind from the consequences of bacterial diseases, announced today ...
-
SaNOtize Obtains Health Canada Approval to Commence Phase II Trial for Potential COVID-19 Therapy
SaNOtize Research and Development Corporation (“SaNOtize” or “the company”) today announced that it has been granted approval by Health Canada to conduct a multiCentre Phase II prevention and efficacy trial for a front-line antiviral prevention and early treatment for use against COVID-19. SaNOtize also announced that new tests conducted by the Institute for Antiviral ...
-
Vaxcyte Doses First Participants in Phase 2 Portion of Ongoing VAX-24 Phase 1/2 Clinical Proof-of-Concept Study in Adults
Following Prespecified Review of Phase 1 Safety and Tolerability Data, Independent Data Monitoring Committee Recommends Study Proceed as Planned Company Expects to Announce Topline Results from Both the Phase 1 and Phase 2 Portions of the Study Evaluating VAX-24 for the Prevention of Invasive Pneumococcal Disease and Pneumonia by the End of 2022 VAX-24 is a 24-Valent Pneumococcal Conjugate ...
-
Health Canada Grants Marketing Authorization for TRIKAFTA (elexacaftor/tezacaftor/ivacaftor and ivacaftor) in Children With Cystic Fibrosis Ages 6 Through 11 years With At Least One F508del Mutation
Approximately 500 Canadians ages 6-11 are now eligible for TRIKAFTA®- Vertex has submitted this indication to CADTH & INESSS for Health Technology Assessments- Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today announced that Health Canada has granted Marketing Authorization for the expanded use of TRIKAFTA® (elexacaftor/tezacaftor/ivacaftor and ivacaftor) to include ...
Need help finding the right suppliers? Try XPRT Sourcing. Let the XPRTs do the work for you